Skip to content
Clinical Trials – home

Hms GmbH

Verified siteinfo

Germany Trierer Strasse 215-217, 66663 Merzig, Germany

  • 6 trials recruiting
  • Hidradenitis · Dermatitis atopic · Psoriasis
  • Adults and children

About Specializations

Hms GmbH in Merzig, Germany specialises in clinical trials of conditions such as Hidradenitis, Dermatitis atopic, Psoriasis, Actinic keratosis, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases

The site concentrates on immune‑mediated skin disorders, aiming to test new systemic agents and assess long‑term safety for conditions such as hidradenitis suppurativa and severe plaque psoriasis.

  • Upadacitinib efficacy in moderate‑to‑severe hidradenitis suppurativa
  • Spesolimab long‑term safety after previous exposure
  • Lutikizumab treatment of hidradenitis signs and symptoms
  • Remibrutinib impact on hidradenitis activity
  • LAD328 proof‑of‑concept in adult hidradenitis patients

Hms GmbH in Merzig supports these investigations with a focused team of two investigators.

Skin and Connective Tissue Diseases

Research at this centre targets psoriasis, atopic dermatitis, and actinic keratosis, evaluating both topical and oral therapies to improve skin health and reduce disease burden.

  • JNJ‑77242113 for moderate‑to‑severe plaque psoriasis
  • Tirbanibulin versus diclofenac for actinic keratosis on face and scalp
  • Deucravacitinib compared with ustekinumab for plaque psoriasis
  • Ruxolitinib 1.5% cream for hidradenitis lesions
  • RO7790121 achieving EASI‑75 response in atopic dermatitis

The Merzig facility provides a patient‑friendly environment for participants across Germany.

Immune System Phenomena

Studies explore immune response modulation and vaccine safety in dermatologic conditions, seeking to understand how targeted therapies affect underlying immunologic pathways.

  • Safety and immunologic response of SHIngrix vaccination in psoriasis or psoriatic arthritis
  • Remibrutinib evaluation of cytokine inhibition in hidradenitis
  • Assessment of cardiovascular safety of long‑term deucravacitinib use

Findings aim to guide clinicians on balancing efficacy with immune‑related risks.

Immune system processes

The program investigates JAK inhibition and related pathways, focusing on sustained safety and therapeutic benefit for chronic inflammatory skin diseases.

  • Long‑term extension study of oral povorcitinib in hidradenitis
  • Selective treatment of oral povorcitinib rollover evaluation
  • IC0624 first‑line therapy trial for mild‑to‑moderate hidradenitis

Both adult and adolescent participants are included to broaden the relevance of the results.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Trierer Strasse 215-21766663 MerzigGermany
Recruiting now
6 trials
Conditions studied
7
Partner status
Verified site

More sites in MerzigGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Hidradenitis

Recruiting

A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Almirall S.A.

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Justus-Liebig-Universitaet Giessen

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.